Leadership Team
Meet our experienced team.
In the development of antibody-drug conjugates (ADCs), linker technologies are a critical component, particularly those used in first-generation ADC bioconjugation. In our experience, these often have limitations that can impact the safety and efficacy of the ADC.
We developed ThioBridge™ to overcome the limitations associated with traditional linker technologies. Improving the design and delivery of ADCs.
Click here to access the info sheet to learn more about the potential benefits of this newly enhanced platform.
We are a leading, fully integrated bioconjugates & ADCs contract development and manufacturing organization (CDMO). For over 20 years we have refined our expertise in bioconjugation and conjugates to create end-to-end solutions including our ThioBridge™ ADC development platform.
You may also be interested in